142 related articles for article (PubMed ID: 36699422)
1. Clinical Features and Outcomes of Patients with Double-Hit/Triple-Hit Multiple Myeloma Detected at Relapse.
Singh C; Panakkal V; Sreedharanunni S; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Malhotra P
Indian J Hematol Blood Transfus; 2023 Jan; 39(1):151-153. PubMed ID: 36699422
[TBL] [Abstract][Full Text] [Related]
2. Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real World.
Singh C; Panakkal V; Sreedharanunni S; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Malhotra P
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e685-e690. PubMed ID: 35422411
[TBL] [Abstract][Full Text] [Related]
3. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
[No Abstract] [Full Text] [Related]
4. [Analysis of the clinical effects and outcome of patients with double-hit high-risk multiple myeloma].
Liu S; Shang J; Lin Y; Wang ZH; Wei TN; Lin L; Yang T; Chen WM
Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1209-1214. PubMed ID: 34794226
[No Abstract] [Full Text] [Related]
5. Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance.
Baysal M; Demirci U; Umit E; Kirkizlar HO; Atli EI; Gurkan H; Gulsaran SK; Bas V; Mail C; Demir AM
Sci Rep; 2020 Apr; 10(1):5991. PubMed ID: 32249811
[TBL] [Abstract][Full Text] [Related]
6. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
Hao S; Lu X; Gong Z; Bassett RL; Hu S; Konoplev SN; Tang G; Li S; Xu J; Khanlari M; Lee HC; Manasanch EE; Weber DM; Orlowski RZ; Medeiros LJ; Lin P
Mod Pathol; 2021 Feb; 34(2):327-335. PubMed ID: 32908255
[TBL] [Abstract][Full Text] [Related]
7. [Epidemiological analysis of cytogenetic abnormalities in patients with newly-diagnosed multiple myeloma: a multi-center retrospective study].
Yuan RF; Dong YJ; Li CR; Huang WR; Zhang LM; Zhu Q; Xu L; Xu YJ; Xu Q; Gao GX; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):10-15. PubMed ID: 32023748
[No Abstract] [Full Text] [Related]
8. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.
De Ramón C; Rojas EA; Cardona-Benavides IJ; Mateos MV; Corchete LA; Gutiérrez NC
Br J Haematol; 2022 Nov; 199(3):344-354. PubMed ID: 35983648
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic analysis of 182 newly diagnosed multiple myeloma patients with high risk cytogenetic abnormalities].
Liu XL; Bai J; Fan HQ; Yang YP; Yue TT; Zhang Y; Yang PY; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):644-649. PubMed ID: 31495130
[No Abstract] [Full Text] [Related]
11. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
Rajkumar SV
Am J Hematol; 2022 Aug; 97(8):1086-1107. PubMed ID: 35560063
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.
Rajkumar SV
Am J Hematol; 2020 May; 95(5):548-567. PubMed ID: 32212178
[TBL] [Abstract][Full Text] [Related]
13. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
[TBL] [Abstract][Full Text] [Related]
14. Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma.
Hlavacek P; Schepart A; Silverstein AR; Petrilla AA; Johnson W; Schroeder A
Future Oncol; 2023 Apr; 19(11):775-787. PubMed ID: 37132520
[TBL] [Abstract][Full Text] [Related]
15. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
16. Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature.
Miao Y; Hu S; Lu X; Li S; Wang W; Medeiros LJ; Lin P
Hum Pathol; 2016 Dec; 58():72-77. PubMed ID: 27544800
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
[No Abstract] [Full Text] [Related]
18. The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China.
Chen Q; Han X; Zheng G; Yang Y; Li Y; Zhang E; Yang L; Dong M; He D; He J; Cai Z
Front Oncol; 2022; 12():1084683. PubMed ID: 36605445
[TBL] [Abstract][Full Text] [Related]
19. Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience.
Kuhlman JJ; Moustafa MA; Jiang L; Iqbal M; Seegobin K; Wolcott Z; Ayala E; Ansell S; Rosenthal A; Paludo J; Micallef I; Johnston P; Inwards D; Habermann T; Kharfan-Dabaja M; Witzig TE; Nowakowski GS; Tun HW
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e815-e825. PubMed ID: 35534379
[TBL] [Abstract][Full Text] [Related]
20. Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14).
Ceglédi A; Csukly Z; Fekete M; Kozma A; Szemlaky Z; Andrikovics H; Mikala G
Pathol Oncol Res; 2023; 29():1611375. PubMed ID: 38025905
[No Abstract] [Full Text] [Related]
[Next] [New Search]
